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Available online 28 January 2016The precise effects of HIV-1 on the gut microbiome are unclear. Initial cross-sectional studies provided
contradictory associations between microbial richness and HIV serostatus and suggested shifts from Bacteroides
to Prevotella predominance following HIV-1 infection, which have not been found in animal models or in studies
matched for HIV-1 transmission groups. In two independent cohorts of HIV-1-infected subjects and HIV-1-
negative controls in Barcelona (n=156) and Stockholm (n=84),menwho have sexwithmen (MSM) predom-
inantly belonged to the Prevotella-rich enterotypewhereasmost non-MSMsubjectswere enriched in Bacteroides,
independently of HIV-1 status, and with only a limited contribution of diet effects. Moreover, MSM had a signif-
icantly richer and more diverse fecal microbiota than non-MSM individuals. After stratifying for sexual orienta-
tion, there was no solid evidence of an HIV-speciﬁc dysbiosis. However, HIV-1 infection remained consistently
associated with reduced bacterial richness, the lowest bacterial richness being observed in subjects with a
virological-immune discordant response to antiretroviral therapy. Our ﬁndings indicate that HIV gutmicrobiome
studies must control for HIV risk factors and suggest interventions on gut bacterial richness as possible novel
avenues to improve HIV-1-associated immune dysfunction.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Bacteroides1. Introduction
The main clinical problems of people living with HIV (PLWH)
in areas with adequate healthcare standards and continued antire-
troviral therapy (ART) supply are increasingly related to premature
aging (Paiardini and Müller-Trutwin, 2013). That is, a precociousDS Research Institute, Ctra de
. This is an open access article underdevelopment of type 2 diabetes, dislipidemia, cardiovascular diseases,
osteoporosis and frailty syndrome. Such diseases have been related to
structural or metabolic perturbations in the gut microbiota of non-
HIV-infected subjects (Claesson et al., 2012; Koeth et al., 2013; Le
Chatelier et al., 2013; Tang et al., 2013) whereas, in PLWH, have been
linked to chronic inﬂammation, immune activation and endotoxemia
(Brenchley et al., 2006; Douek, 2003; Sandler and Douek, 2012). Thus
there is considerable interest in understanding the role of the human
gut microbiome in HIV pathogenesis and, in particular, its ability to
perpetuate chronic inﬂammation and foster immune senescence. This
has immediate clinical implications because, in theory, it might bethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Baseline chacteristics of subjects in the Barcelona test dataset (BCN0).
Full dataset HIV-1 positive HIV-1 negative p-Value
No. of subjects 156 129 27
Age (years)a 43 (35, 51) 44 (36, 52) 37 (34, 44) 0.021
Gender Male 124 (79.5%) 101 (78.3%) 23 (85.2%) 0.076 0.600
Female 31 (19.9%) 28 (21.7%) 3 (11.1%) 0.291
Transgender 1 (0.6%) 0 1 (3.7%) 0.173
Ethnicity Asiatic 1 (0.6%) 1 (0.8%) 0 0.900 1
Caucasian 124 (79.5%) 101 (78.3%) 23 (85.2%) 0.600
Hispanic–Latino 28 (18%) 24 (18.6%) 4 (14.8%) 0.786
Others 3 (1.9%) 3 (2.3%) 0 1
Risk group HTS 41 (26.3%) 37 (28.7%) 4 (14.8%) 0.027 0.156
MSM 100 (64.1%) 77 (59.7%) 23 (85.2%) 0.014
PWID 15 (9.6%) 15 (11.6%) 0 0.075
Residency Barcelona 51 (32.7%) 36 (27.9%) 15 (55.6%) 0.058 0.007
BCN Met 56 (35.8%) 50 (38.8%) 6 (22.2%) 0.125
Outside BCN Met 38 (24.4%) 33 (25.6%) 5 (18.5%) 0.622
na 11 (7.1%) 10 (7.7%) 1 (3.7%) 0.691
Proﬁle Late presenter 11 (7.1%) 11 (8.5%) 0 – –
Discordant 18 (11.5%) 18 (14%) 0 –
Concordant 53 (34%) 53 (41.1%) 0 –
Early-treated 13 (8.3%) 13 (10.1%) 0 –
Naïve 15 (9.6%) 15 (11.6%) 0 –
Viremic control 11 (7.1%) 11 (8.5%) 0 –
Elite control 8 (5.1%) 8 (6.2%) 0 –
HIV-1 negative 27 (17.3%) 0 27 (100%) –
BMI (kg/m2)a 23.8 (22, 26) 23.8 (22, 26) 24.9 (22, 27) 0.469
Allergy No 122 (78.2%) 101 (78.3%) 21 (77.8%) 0.205 1
Yes 30 (19.2%) 26 (20.2%) 4 (14.8%) 0.603
na 4 (2.6%) 2 (1.5%) 2 (7.4%) 0.138
ATB during the previous
3–6 months
35 (22.4%) 32 (24%) 4 (14.8%) 0.446
Fecal consistency Hard 56 (35.9%) 44 (34.1%) 12 (44.4%) 0.535 0.378
Soft 91 (58.3%) 77 (59.7%) 14 (51.9%) 0.521
Liquid 5 (3.2%) 5 (3.9%) 0 0.588
na 4 (2.6%) 3 (2.3%) 1 (3.7%) 0.536
Abdominal transit alterations Yes 23 (14.7%) 22 (17.1%) 1 (3.7%) 0.089 0.134
No 127 (81.4%) 103 (79.8%) 24 (88.9%) 0.414
na 6 (3.9%) 4 (3.1%) 2 (7.4%) 0.277
Defecation frequency (per day) 1 88 (56.4%) 70 (54.3%) 18 (66.7%) 0.669 0.288
2 47 (30.1%) 40 (31%) 7 (25.9%) 0.653
3 12 (7.7%) 11 (8.5%) 1 (3.7%) 0.692
4 5 (3.2%) 5 (3.9%) 0 0.588
na 4 (2.6%) 3 (2.3%) 1 (3.7%) 0.536
HBV co-infection Positive 19 (12.2%) 19 (14.7%) 0 0.054 0.045
Negative 112 (71.8%) 91 (70.6%) 21 (77.8%) 0.638
na 25 (16%) 19 (14.7%) 6 (22.2%) 0.386
HCV co-infection Positive 24 (15.4%) 24 (18.6%) 0 0.013 0.015
Negative 120 (76.9%) 94 (72.9%) 26 (96.3%) 0.005
na 12 (7.7%) 11 (8.5%) 1 (3.7%) 0.692
Syphilis serology Positive 21 (13.5%) 20 (15.5%) 1 (3.7%) 0.262 0.128
Negative 116 (74.3%) 93 (72.1%) 23 (85.2%) 0.225
na 19 (12.2%) 16 (12.4%) 3 (11.1%) 1
PCR Chlamydia trachomatis Positive 9 (5.8%) 9 (7.0%) 0 0.161 0.360
Negative 115 (73.7%) 91 (70.5%) 24 (88.9%) 0.055
na 32 (20.5%) 29 (22.5%) 3 (11.1%) 0.293
PCR Neisseria gonorrhoeae Positive 0 0 0 0.109
Negative 125 (80.1%) 100 (77.5%) 25 (92.6%)
na 31 (19.9%) 29 (22.5%) 2 (7.4%)
PCR human papilloma virus Yes 72 (46.2%) 61 (47.3%) 11 (40.7%) 0.613 0.671
No 83 (53.2%) 67 (51.9%) 16 (59.3%) 0.530
na 1 (0.6%) 1 (0.8%) 0 1
Anal cytology ASCUS 22 (14.1%) 17 (13.2%) 5 (18.5%) 0.664 0.542
HSIL 7 (4.5%) 7 (5.4%) 0 0.605
LSIL 30 (19.2%) 26 (20.2%) 4 (14.8%) 0.603
Normal 80 (51.3%) 64 (49.6%) 16 (59.3%) 0.402
na 17 (10.9%) 15 (11.6%) 2 (7.4%) 0.738
CD4+ T-cell count (cells/mm3)a All – 700 (462, 860) – – –
Late presenters – 100 (33, 189) – –
Discordant – 263 (223, 287) – –
Concordant – 761 (640, 932) – –
Early-treated – 785 (506, 930) – –
ART naive – 701 (564, 813) – –
Viremic control – 783 (525, 920) – –
Elite control – 940 (821, 1009) – –
Lymphocytes (×10×9/L)a 2 (1.7, 2.5) 2 (1.6, 2.5) 2.1 (1.8, 2.3) 0.438
Leukocytes (×10×9/L)a 5.8 (4.8, 7.2) 5.6 (4.8, 6.7) 7.1 (5.2, 8.4) 0.011
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Table 1 (continued)
Full dataset HIV-1 positive HIV-1 negative p-Value
No. of subjects 156 129 27
HIV-1 RNA (copies/mL)a Late presenters – 178,500 (61,880, 340,300) – –
Discordant – b40 (b40, b40) – –
Concordant – b40 (b40, b40) – –
Early-treated – b40 (b40, b40) – –
ART naive – 13,900 (6867, 43,410) – –
Viremic control – 794 (243, 1360) – –
Elite control – b40 (b40, b40) – –
HTS, heterosexual; MSM, men who have sex with men; PWID, people who inject drugs; ATB, antibiotic; BCN Met, Barcelona Metropolitan Area; na, not available.
a Median (IQR), p-values for continuous and discrete variables were calculated with the Wilcoxon rank sum and Fisher's tests, respectively.
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states with the host, which might allow, for example, to achieve
faster immune reconstitution, improve vaccine responses or reduce
HIV reservoirs.
However, although expectations are high, the HIV microbiome
science is still at its early stages, andmuch remains to be known. Simple
questions such as whether there is a consistent HIV-speciﬁc dysbiosis
pattern, or which factors are relevant in shaping the microbiome in
PLWH remain unanswered. Initial cross-sectional studies in humans
have provided contradictory associations between microbial richness
and HIV serostatus, and suggested shifts from Bacteroides to Prevotella
predominance following HIV-1 infection (Lozupone et al., 2013;
Vázquez-Castellano et al., 2015). Such shifts, however, have neither
been found in animal models (Handley et al., 2012) nor in studies
matching for HIV-1 risk groups (Yu et al., 2013). Conversely, large inter-
national studies in healthy populations have shown that at least in
resource-rich countries, the gut microbiome forms a composition land-
scape with density peaks that can stratify the human population into
enterotypes dominated by Bacteroides, Prevotella and Ruminococcus,
respectively (Arumugam et al., 2011; Koren et al., 2013). The origin
and clinical signiﬁcance of such enterotypes is uncertain, but they
have been linked to genetic (Goodrich et al., 2014), as well as to lifestyle
(Clarke et al., 2014; David et al., 2013;Wu et al., 2011) and environmen-
tal factors (Modi et al., 2014; Sommer and Bäckhed, 2013), including
long-term dietary patterns and exercise. Thereby, associations between
Prevotella or Bacteroides and HIV infection might be easily confounded
by other factors. Obtaining reliable information at this level is critical
to advance our understanding of HIV pathogenesis, as well as to deﬁne
the speciﬁc targets of novel therapeutic interventions on the human
gut microbiome.
2. Methods
2.1. Study Design
This was a cross-sectional study in two independent European
cohorts of HIV-1-infected subjects and HIV-negative controls. The
study included one test cohort, one internal validation cohort and one
external validation cohort (Supplementary Fig. 1).
The test cohort (BCN0) was enrolled in Barcelona, Catalonia,
Spain, between January and December 2014. HIV-1 infected patients
were recruited from HIV Clinics at the University Hospitals Germans
Trias i Pujol and Vall d'Hebrón. HIV-1-negative controls were mainly
recruited from an ongoing prospective cohort of HIV-negative MSM
at risk of becoming infected by HIV-1 (Coll et al., 2015), who attend
quarterly medical and counseling visits including HIV-1 testing
(Alere Determine™ HIV-1/2 Ag/Ab Combo, Orlando, FL) at a
community-based center for MSM in Barcelona (Meulbroek et al.,
2013). Additional controls were HIV-1-negative partners from HIV-1-
infected subjects attending the HIV clinics.
The inclusion criteria were: age within 18 and 60 years and body
mass index (BMI) within 18.5 and 30. Exclusion criteria were: (a) any
gross dietary deviation from a regular diet, or any speciﬁc regular diet,i.e., vegetarian, low-carb, etc.; (b) antibiotic use during the previous
3 months (with the exception of late presenters, who could receive an-
tibiotics to treat opportunistic infections); (c) pregnancy or willingness
to become pregnant; (d) current drug consumption or alcohol abuse;
(e) any chronic digestive disease such as peptic ulcer, Crohn's disease,
ulcerative colitis or coeliac disease; (f) any surgical resection of the
intestines except for appendectomy; (g) any autoimmune disease;
and (h) any symptomatic chronic liver disease or presence of hepatic
insufﬁciency deﬁned as a Child–Pugh C score. In addition, HIV-infected
subjects were classiﬁed as elite controllers, viremic controllers,
ART-naïve, early treated, late presenters, immune concordant or
immune discordant (Supplementary methods).
The internal validation cohort (cohort BCN1) included individuals
from BCN0 who provided a second fecal sample one month later.
Observations in Barcelona were externally validated in an inde-
pendent observational cohort recruited at the HIV outpatient clinic,
Karolinska University Hospital, Stockholm, Sweden (cohort STK).
All HIV-1-infected patients in cohort STK were at least 18 years old,
had been diagnosed with HIV-1 between one and 25 years earlier
and were ART-naïve at the time of fecal sampling. Controls were
healthy HIV-1-negative individuals matched by sex and age. Neither
patients nor controls had been prescribed antibiotics or probiotics, or
had had infectious diarrhea during the preceding two months.
2.2. Data Collection
Clinical and laboratory data fromBCN0 and BCN1were collected in a
centralized database speciﬁcally designed for this study (OpenClinica™,
© 2015OpenClinica, LLC). The clinical evaluationwasperformed follow-
ing a standardized questionnaire including: a checklist for fulﬁllment of
inclusion and exclusion criteria, anthropometric data, age at study
entry, age at HIV diagnosis, gender, ethnicity, city of residence, HIV
risk group, history of allergies, antibiotic intake between 3 and 6months
before inclusion, frequency and consistency of feces, history of medical
or surgical problems or interventions, present and previous ART,
history of AIDS- and non-AIDS-related diseases, nadir and most recent
CD4+ T-cell counts, HIV-1 RNA levels, history of sexually transmitted
diseases and infection by the human papillomavirus (HPV), hepatitis B
(HBV) or hepatitis C (HCV).
HIV-1 risk categories in our study were mutually excluding: male
study participants who reported being MSM or referred insertive or
receptive anal intercourse with other men were included in the MSM
category, even if they also reported intravenous drug use or sex with
women. Females andmales not included in theMSM category reporting
past intravenous drug use were classiﬁed as PWID. Heterosexual males
or females not included in any of the previous 2 categories were
classiﬁed as HTS. None of our study participants belonged to any other
HIV-1 transmission category.
Study participants in Barcelona received a thorough dietary and
nutritional assessment by a specialized dietitian/nutritionist using two
standardized and validated questionnaires, i.e.: (a) a prospective dietary
nutrient survey aimed at recording, as precisely as possible, any food,
supplement or liquid intake during 3 to 5 consecutive days, including
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week, on average, during the last year.
Participants also went through a proctology evaluation by a special-
ized HIV physician/proctologist. In addition to visual inspection for anal
or perianal lesions, HPV-related or not, the physician performed a rectal
swab to rule out Chlamydia trachomatis andNeisseria gonorrhoeae infec-
tion using real-time PCR and an anal cytology. If the anal cytology
reported an abnormal result, such as ASCUS (atypical squamous cells
of undetermined signiﬁcance), LSIL (low-grade squamous intraepithelial
lesion) or HSIL (high-grade squamous intraepithelial lesion), the subject
was properly treated and PCR typing of HPV was performed. No cases of
anal cancer were detected.
In all study participants, we produced MiSeq™ 16S rRNA sequence
data on fecal microbiomes and measured soluble plasma markers
of enterocyte damage (intestinal fatty acid-binding protein, IFABP), mi-
crobial translocation [soluble CD14 (sCD14) and lipopolysaccharide
binding protein (LBP)] and systemic inﬂammation [interleukin-6
(IL-6), C-reactive protein (CRP) and interferon-gamma-inducible
protein-10 (IP-10)].
Study participants collected fecal samples in sterile fecal collec-
tion tubes the same day or the day before their clinical appointment,
before the proctology exam, and following instructions pre-speciﬁed
on standard operating procedures. If required, samples were stored
at 4 °C overnight until DNA extraction. All samples collected in
Barcelona were immediately extracted upon arrival to the laborato-
ry. Additional aliquots were cryopreserved at−80 °C for future stud-
ies. Samples collected in Stockholm were cryopreserved at −80 °C
and shipped on dry ice in batch to the IrsiCaixa AIDS Research Insti-
tute, where they were extracted, ampliﬁed, sequenced and analyzed
using the exact same procedures applied to the Barcelona samples.
The lag times to freezing were always b36 h and no particular
chemical stabilizers were added to samples used for the analyses
presented here. Fecal sample collection procedures were the same
for cases and controls.
Detailed descriptions of the wet-lab procedures and the ecological
and statistical analyses of the microbiome, soluble plasma markers
and the nutritional assessment are available in the Supplementary
methods section.Table 2
Baseline chacteristics of subjects in the Stockholm validation dataset (STK).
Full dataset
No. of subjects 84
Age (years) 40 (32, 48)
Gender Male 51 (60.7%)
Female 33 (39.3%)
Risk group HTS 55 (66.5%)
MSM 19 (22.6%)
PWID 10 (11.9%)
Ethnicity Asian 2 (2.4%)
Black 28 (33.3%)
Caucasian 52 (61.9%)
Hispanic–Latino 2 (2.4%)
Country of origin Sweden 39 (46.4%)
Kenya 5 (5.9%)
Finland 4 (4.8%)
Ethiopia 3 (3.6%)
Eritrea 3 (3.6%)
Nigeria 3 (3.6%)
Uganda 3 (3.6%)
Other 24 (28.5%)
CD4+ T-cell count (cells/mm3)a –
CD4+ T-cell count (%)a –
CD8+ T-cell count (cells/mm3)a –
CD8+ T-cell count (%)a –
HIV-1 RNA copies/mLa –
a Median (IQR), p-values for continuous and discrete variables were calculated with the Wi2.3. Ethics & Community Involvement
The study was reviewed and approved by the Institutional Review
Boards of the Hospital Universitari Germans Trias i Pujol (reference
PI-13-046) and the Hospital Vall d'Hebrón (reference PR(AG)109/2014).
The Stockholm study cohort was approved by the Regional Ethical
Committee (Stockholm, Sweden, Dnr 2009-1485-31-3). All participants
provided written informed consent in accordance with the World
Medical Association Declaration of Helsinki. The study concept, design,
patient information and results were discussed with the IrsiCaixa's
Community Advisory Committee, who also provided input on the
presentation and dissemination of study results (Supplementary
methods).
2.4. Sequence and Data Availability
Raw Illumina MiSeq sequences and study metadata were deposited
in the National Center for Biotechnology Information— NCBI repository
(Bioproject accession number: PRJNA307231, SRA accession number:
SRP068240).
2.5. Financial Support and Role of the Funding Sources
This study was mainly funded through philanthropy and private
donations, which had no inﬂuence on its contents. Fundswere obtained
from a personal donation fromMr. Rafael Punter, the Gala contra la SIDA
2013 and 2014 editions, and the Nit per la Recerca a la Catalunya Central
2015 edition. M.R. is funded through a FI-DGR grant (FI-B00184) from
Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) at the
Secretaria d'Universitats i Recerca del Departament d'Economia i
Coneixement de la Generalitat de Catalunya. Y.G. is supported through a
post-doctoral grant from the Fundación Paideia Galiza. M.C. is funded
through the Red de Investigación en SIDA, RD12/0017/0002 as part
of the Plan Nacional R + D + I and coﬁnanced by the Instituto de
Salud Carlos III (ISCIII)-Subdirección General de Evaluación y el Fondo
Europeo de Desarrollo Regional (FEDER). J.R. is supported through a
grant for doctoral studies from Noel Alimentaria to the University
of Vic (UVic-UCC). B.M. is a Joan Rodés investigator from the ISCIIIHIV-1 positive HIV-1 negative p-Value
77 7
38 (32, 49) 44 (38, 47) 0.615
46 (59.7%) 5 (71.4%) 0.699
31 (40.3%) 2 (28.6%)
48 (62.3%) 7 (100%) 0.214
19 (24.7%) 0
10 (13.0%) 0
2 (2.6%) 0 1
26 (33.8%) 2 (28.6%)
47 (61.0%) 5 (71.4%)
2 (2.6%) 0
34 (43.4%) 5 (71.4%) 0.069
5 (6.5%) 0
4 (5.2%) 0
1 (1.3%) 2 (28.6%)
3 (3.9%) 0
3 (3.9%) 0
3 (3.9%) 0
24 (31.2%) 0
480 (380, 630) – –
26 (20, 32) – –
970 (660, 1290) – –
51 (44, 59) – –
19,100 (1590, 69,900) – –
lcoxon rank sum and Fisher's tests, respectively.
Fig. 2. Alpha diversity by HIV-1 phenotype. HIV-1-infected subjects with an immune discordant phenotype (i.e. those who do not recover CD4+ counts N300 cells/mm3 despite at
least 2 years of effective antiretroviral therapy) had the lowest microbiome richness of all HIV-1 phenotypes. Individuals with an immune concordant phenotype (i.e., those achieving
CD4+count reconstitution N500 cells/mm3 on antiretroviral therapy) also had lowermicrobiome richness thanHIV-1-negative individuals, but not as low as immune discordant subjects.
“Simpson” refers to 1-Simpson index. The remaining ecological index names are self-explanatory. Comparisons were done using a Kruskal–Wallis test including post-hoc pairwise
analyses. Benjamini–Hochberg-adjusted p-values are shown at the top of each index; for post-hoc pairwise comparisons: *p b 0.1, **p b 0.05, ***p b 0.001.
Fig. 1. Both HIV transmission group and HIV-1 infection are linked to the human fecal microbiome richness and diversity. a) The highest richness and diversity in human fecal microbiota
were observed in men who have sex with men (MSM). There were no differences between heterosexual subjects (HTS) and people who acquired HIV-1 infection through intravenous
drug use (PWID). Kruskal–Wallis p-values in a were adjusted for multiple comparisons using the Benjamini–Hochberg method. b) HIV-1 infection was associated with signiﬁcant
reductions in fecal human microbiome richness after stratifying for sexual preference. Comparisons were made with the Wilcoxon rank sum test with continuity correction. All alpha
diversity ﬁndings were consistent in Barcelona (test cohort, month 0) (BCN0) and Stockhom (STK). Identical results were found in BCN at month 1 (Supplementary Fig. 2) and when
using an independent sequence analysis pipeline (Supplementary Fig. 14). Note: “Simpson” refers to 1-Simpson index. The remaining ecological index names are self-explanatory.
*p b 0.1, **p b 0.05, ***p b 0.001.
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Fig. 3. Spearman correlation by genus abundance. Only signiﬁcant values (Holm's-corrected p b 0.05) are shown. The plot conﬁrms previous observations, i.e.: a) strong positive
correlations between Bacteroides, Parabacteroides, Barnesiella, Alistipes and Odoribacter, b) strong positive correlations between Prevotella, Alloprevotella,Mitsuokella and Intestinimonas,
among others, and c, strong inverse correlations between the groups including Prevotella and Bacteroides.
140 M. Noguera-Julian et al. / EBioMedicine 5 (2016) 135–146(JR13/00024), Madrid, Spain. M.L.C. is funded through the
grant MTM2012-38067-C02-02, Spanish Ministry of Economy and
Competitiveness, Spain. PB, FH and GZ are supported by the European
Molecular Biology Laboratory. F.H. was funded from the European
Union's Horizon 2020 research and innovation program under the
Marie Skłodowska-Curie grant agreement no. 600375. P.B. acknowl-
edges the European Research Council grant Cancerbiome, reference
268985. The sponsors of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of the report.
The corresponding author had full access to all study data, and had
ﬁnal responsibility for the decision to submit for publication.Fig. 4. The bacterial genus composition of the human fecal microbiome is mainly linked to H
Barcelona test dataset (BCN0) was largely determined by HIV transmission group, with MSM
with mean abundance of at least 2% across all samples are represented in colors; those wit
individual. A similar plot for the Stockholm cohort is shown in Supplementary Fig. 12. b) Non-m
thatmicrobiomes in theBCN0, BCN1and STKdatasetsmainly cluster byHIV transmission group
plots using other distances are shown in Supplementary Figs. 8 to 10. c) Partitioning aroundmed
better explained by 2 rather thanmore clusters, with reasonable Silhouette support. This inform
box plots showing thatMSMwere enriched in Prevotella andnon-MSM(HTS or PWID)were enr
highly signiﬁcant (p b 0.001) after adjusting for multiple comparisons using the Benjamini–Hoc
MSM categories are shown in the Supplementary Figs. 13 to 15.3. Results
3.1. Study Subjects
The study included 240 individuals, 156 in Barcelona (Table 1) and
84 in Stockholm (Table 2). The test cohort BCN0 comprised 129
(82.7%) HIV-1-infected and 27 (17.3%)HIV-negative subjects. The inter-
nal validation cohort BCN1 included 110 individuals, 87 HIV-1-infected
(79.1%) and 23 non-HIV-infected (20.9%). The external validation
cohort STK had 77 HIV-1-infected (91.6%) and 7 non-HIV-infected
individuals (8.4%). In Barcelona, the median age of study participantsIV transmission group. a) The bacterial genus composition of the fecal microbiota in the
being enriched in the Prevotella cluster and non-MSM in the Bacteroides cluster. Genera
h b2% abundance are grouped into the category “Others”. Each column represents one
etric multidimensional scaling (NMDS) ordination plots of Bray–Curtis distances showing
(MSMvs. non-MSM) rather thanbyHIV serostatus. Ellipses include 95% of samples. Similar
oids (PAM) analysis of the BCN0dataset showing this population structure in this dataset is
ationwas used to deﬁne the Bacteroides and Prevotella clusters in our study. d) Abundance
iched inBacteroides. ComparisonsbetweenMSMand thenon-MSMcategorieswere always
hberg method. Plots of all genera showing signiﬁcant differences betweenMSM and non-
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Eighty percent of subjects were men, mostly from Caucasian ethnicity.
Sixty-four percent of all subjects were MSM, 26% HTS and 10% PWID.
There were 8 (5.1%) elite controllers, 11 (7.1%) viremic controllers,
15 (9.6%) ART-naïve, 13 (8.3%) early-treated, 53 (34.1%) immune con-
cordant, 18 (11.5%) immune discordant, and 11 (7.1%) late presenters.
HIV-1-infected subjects were slightly older and were more likely to be
HBV and HCV positive than HIV-negative controls. Groups were
well balanced in all other factors. In Stockholm, 60% of subjects
were men; 23% were MSM, 66% HTS and 11% PWID. Only half were
nationals from Scandinavian countries; 62% individuals were Caucasian
and 33% were Black.3.2. Richness and Diversity of the Fecal Microbiota
The fecal microbiota was signiﬁcantly richer and more diverse in
MSM than non-MSM individuals in both cities, also after correcting
for multiple comparisons (Fig. 1, Supplementary Figs. 2 and 14). This
indicated that the measurement of the effect of HIV-1 on gut microbialFig. 5. Global microbiota classiﬁer by sexual preference group and HIV-1 status. A and C) Rela
infection, respectively, are displayed as heatmap of log-abundance z-scores with the direction
classiﬁer only includes MSM subjects. The mean contribution of each marker species to the cl
Below each heatmap the classiﬁcation score of the microbial signature from cross-validation
heatmap (see color key). B and D) Cross-validation accuracy of the microbiota classiﬁer is dep
made in ten times resampled tenfold cross-validation with the area under the curve (AUC) i
microbiome genus composition and sexual orientation, whereas the association with HIV-1 inrichness and diversity had to take HIV transmission group into account.
After stratifying for MSM vs. non-MSM, HIV-1 infection remained con-
sistently associated with reduced bacterial richness (15% to 30%
reduction relative to HIV-negative individuals) in both groups and
both cities (Fig. 1, Supplementary Figs. 2 and 14). In the Barcelona
cohort, the lowest microbial richness and diversity was observed
among HIV-1-infected individuals with an immune-virological dis-
cordant phenotype (Fig. 2). Subjects with an immune-virological
concordant phenotype had higher microbial richness than immune
discordant individuals, but, nevertheless, still showed reduced
microbial richness relative to HIV-negative controls, suggesting
that despite adequate immune recovery [median (IQR) CD4+ T-cell
counts: 761 (640, 932) cells/mm3] at the time of testing, ART had not
been able to fully normalize microbial richness.3.3. Bacterial Composition of the Fecal Microbiota
Clustering of the fecal microbiomes in BCN0 and STK using
a partitioning around medoids (PAM) algorithm suggested thetive abundances of 28 gut microbial genera collectively associated with MSM and HIV-1
of association indicated to the left. To avoid confounding by sexual preference, the HIV-1
assiﬁcation is shown to the left (bars correspond to log-odds ratio in logistic regression).
is shown as gray scale. HIV-1 status and HIV-1 risk group are color-coded below the ﬁrst
icted as receiver–operator-characteristic (ROC) curve summarizing mean test predictions
ndicated inside each plot. As shown, there was a strong association between the global
fection was much weaker and of uncertain signiﬁcance.
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(Fig. 4c). Such clusters were enriched either in Bacteroides or
Prevotella, and had a similar bacterial composition to the corresponding
previously described enterotypes (Arumugam et al., 2011; Koren et al.,
2013) (Supplementary Fig. 3). As expected from previous work on gut
enterotypes, there were strong positive correlations between the genus
Bacteroides and Parabacteroides, Barnesiella, Alistipes and Odoribacter,
as well as between Prevotella and Alloprevotella, Catenibacterium,
Mitsuokella and Intestinimonas, among others (Fig. 3), highlighting that
differences between the groups extended beyond a single genus. TheFig. 6. Limited effect of diet on the composition of the microbiome. a) Subjects belonging to th
energy intake. Therefore, all subsequent nutritional analyses were normalized for this factor
and food portions (right), according to a Dirichlet multinomial regression model. Positive
proportional to the strength of the association. c) Of all links identiﬁed by the Dirichlet a
comparisons (Benjamini–Hochberg FDR b 0.1) were increased consumption of meat in the clu
between normalized amounts of nutrients and Bray–Curtis distance to the furthest subject i
shorter distance to each cluster. Therefore, values in red and blue represent increased and
the direction of the correlations was concordant with previous publications, note the small ef
after correction for multiple comparisons (Benjamini–Hochberg FDR b 0.1); Permanova p =
the differences between clusters in consumption of nutrients (e) and portions of food (f). Comgenera correlating with Prevotella were negatively correlated with
Bacteroides and vice versa. Moreover, themicrobiomes of the Bacteroides
and Prevotella clusters showed remarkably different functional proﬁles
(Supplementary Figs. 4 and 5), also in agreement with previous
enterotype descriptions (Arumugam et al., 2011).
3.4. Factors Associated With the Fecal Microbiota Composition
Weexplored variables potentially inﬂuencing the composition of the
fecal microbiomes, according to a univariate ADONIS test of ecologicale Prevotella cluster and men who had sex with men (MSM) had signiﬁcantly higher total
. b) Main associations between bacterial genera, normalized amounts of nutrients (left)
and negative associations are shown in red and blue, respectively. Line thickness is
pproach, the only signiﬁcant differences between groups after adjusting for multiple
ster Bacteroides and increased intake of dietary water in MSM. d) Spearman correlations
n the opposite cluster. Negative correlations imply increased amounts of nutrient with
decreased amounts of nutrients within each cluster, respectively. Although, in general,
fect sizes (R2 below the color key). None of the comparisons were statistically signiﬁcant
0.20 for overall differences between clusters. e, f) Mean and 95% conﬁdence intervals for
parisons were signiﬁcant if the 95 conﬁdence interval did not cross 0 (dashed red line).
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consistency, place of residency, ethnicity, HIV-1 serostatus and altered
abdominal transit (Supplementary Table 1). However, only the HIV-1
risk group retained statistical signiﬁcance in a multivariate ADONIS
analysis with terms added sequentially (R2: 0.373, p b 0.001).
Fecal microbiomes in BCN0, BCN1 and STK clustered by HIV trans-
mission group rather than by HIV-1 serostatus, using either Bray–Curtis
(Fig. 4b) or other ecological distances (Supplementary Figs. 6 to 8).
Although a few individuals showed marked differences between the
two time points, fecal microbiota ordination was highly concordant be-
tween BCN0 and BCN1 (Procrustes m2 = 0.3475, PROTEST p = 0.001)
(Supplementary Fig. 9), indicating that differences in microbial ordina-
tion were not due to random variation. The fecal microbiota composi-
tion in both BCN0 and STK signiﬁcantly differed by HIV transmission
group, with MSM and non-MSM subjects mostly belonging to the
Prevotella and Bacteroides clusters, respectively (Fig. 4a and 4d and
Supplementary Figs. 10 to 14). Alpha and beta diversity and genus
abundance analyses were reproducible using a different analysis
pipeline (Hildebrand et al., 2014) (Supplementary Fig. 14 and
Supplementary methods).
In an analysis accounting for the potential interdependency of sexual
preference andHIV-1 serostatus (LEfSe) (Segata et al., 2011), therewere
consistent differences in both cities only by sexual preference group,
with enrichment of Prevotella, Alloprevotella, Succinvibrio, Dorea,
RC 9 gut group, Desulfovibrio, Phascolarctobacterium and unclassiﬁed
Bacteroidales inMSM, and enrichment in Bacteroides, Odoribacter and
Barnesiella in non-MSM individuals (Supplementary Fig. 15).
3.5. Strength of the Associations
To quantify the strength of the association between HIV transmis-
sion group, HIV serostatus and global fecal microbiota composition,
we applied a previously validated global microbiota classiﬁcation con-
cept based on LASSO regression (Zeller et al., 2014) to our BCN0 dataset.
Cross-validation accuracy was extraordinarily high for sexual prefer-
ence group (mean AUC= 95%), conﬁrming a different fecal microbiota
composition in MSM and non-MSM individuals (Fig. 5). In contrast,
HIV-1 status was not associated with consistent changes in the global
fecal microbiota composition at the genus level, suggesting that the
reduction in microbial richness observed in HIV-infected individuals
was not genus-speciﬁc.
Relative to non-MSM subjects, MSMwere younger, weremore likely
to live in Barcelona City, reported softer fecal consistency, andwere less
likely to be infected with HBV and HCV (Supplementary Table 2).
However, none of these factors among others were likely to confound
the previous LASSO models (Supplementary Fig. 16). Although long-
term dietary patterns have been linked to alternative enterotype states
(Wu et al., 2011), the effect of diet on microbiota composition was
limited in our setting (Fig. 6 and Supplementary Fig. 17) and none of
the diet components was selected by multivariate LASSO regression as
a consistent predictor of microbiota clustering.
3.6. Consequences on Enterocyte Damage, Microbial Translocation and
Systemic Inﬂammation
Markers of enterocyte damage, microbial translocation and systemic
inﬂammation followed an overall predictable response across different
HIV phenotypes (Brenchley and Douek, 2012), being generally higher
in immune discordant and late presenters (Supplementary Figs. 18
and 19). However, they did not differ between the Bacteroides or
Prevotella clusters or between MSM and non-MSM individuals.
4. Discussion
In two independent European cohorts with different ethnic and
cultural background, the fecal microbiota of MSM was consistentlyricher and more diverse than that of non-MSM subjects, and was
systematically enriched in genera from the Prevotella enterotype. The
strength of such association was unusually high, reaching 95% accuracy
in a microbial composition-based classiﬁer. These ﬁndings have impor-
tant implications for HIV microbiome science. To our knowledge, this is
the ﬁrst evidence that, in addition to genetic (Goodrich et al., 2014),
lifestyle (Clarke et al., 2014; David et al., 2013; Wu et al., 2011) and
environmental factors (Modi et al., 2014; Sommer and Bäckhed,
2013), factors related with sexual preference might also affect the gut
microbiota composition.
Based on our ﬁndings, previous associations between HIV infection
and Prevotellamight be explained by enrichment of HIV-infected groups
by MSM relative to HIV-negative controls selected from hospital or
research staff, gut biopsy donors, or college students (Lozupone et al.,
2013;Mutlu et al., 2014; Vázquez-Castellano et al., 2015). Contradictory
associations between HIV infection andmicrobial richness could also be
affected by unbalances in the proportion of MSM between groups.
Of note, a selection bias as such could also affect the interpretation of
in silico inferences on bacterialmetabolism, or even directmetabolomic
or metatranscriptomic measurements, which also rely on bacterial
composition.
In concordancewith data from animal models (Handley et al., 2012)
and studies matching for HIV risk factors (Yu et al., 2013), we were
unable to identify a consistent HIV-speciﬁc fecal dysbiosis pattern
after stratifying for HIV transmission group. Yet, HIV-1 infection
remained associated with reduced bacterial richness independently of
sexual orientation, indicating that the most evident hallmark of HIV in-
fection on the gut microbiome is, like in other intestinal inﬂammatory
diseases (Manichanh et al., 2012), a reduction in bacterial richness. In
line with previous observations linking bacterial richness with immune
dysfunction (Nowak et al., 2015), the lowest bacterial richness was
found in immune discordant subjects, followed by immune concordant
individuals with adequate immune recovery on ART. Conversely,
bacterial richness was conserved in subjects initiating ART during the
ﬁrst 6 months of HIV infection, as well as in ART-naïve individuals
with N500 CD4+ counts/mm3, suggesting that early ART initiation
might help to preserve gut microbial richness.
The strong epidemiological association of fecal microbiota composi-
tionwith sexual orientation in two independent cities is yet to be trans-
lated into speciﬁc mechanisms. We ruled out multiple confounders and
only found a limited effect of diet in our setting.We did not collect infor-
mation on exercise, but exercise has been linked to fecal microbiota
composition in athletes (Clarke et al., 2014) and even in them diet
plays an important role. A formal assessment of the socioeconomic
status of our patients was out of the scope of this work, although
based on our ﬁndings, rigorous studies assessing the role of socioeco-
nomic status in the fecal microbiota composition are needed.
Non-MSM subjects in our study were older and more likely to be
co-infected with HBV and HCV than MSM, reﬂecting current trends
of the HIV epidemic in Europe, i.e.: most new HIV-1 infections
occur in youngMSMwho rarely use intravenous drugs. Fecal consisten-
cy was also softer in MSM than in non-MSM subjects, which, indirectly,
might reﬂect better overall health habits, including a healthier diet,
higher water consumption and physical activity. However, none
of these factors, nor ethnicity, achieved a signiﬁcant weight in
LASSO models.
Further studies are needed to evaluate the existence of ecological ad-
aptations of commensal bacteria to changes in gut mucosa induced by
sexual practices. Populations of commensal bacteria are controlled by
substrate competition and glycan availability (Koropatkin et al., 2012)
and several factors might affect distal colorectal mucosa, including
hyperosmolar substances like semen or certain lubricants (Fuchs et al.,
2007;McGowan, 2012), colorectal cleansing or use of sexual toys. Longi-
tudinal studies should also clarify if the observed association is stable
over time, and if it varies according to the number of sexual partners
(i.e., long-term single relationships versus frequent partner exchange)
145M. Noguera-Julian et al. / EBioMedicine 5 (2016) 135–146or by insertive versus receptive anal sex. It is also important to clarify if
the observed association remains in heterosexual women who engage
in receptive anal sex and if increased microbiota richness can be related
to person-to-person transmission of commensal bacteria. Future studies
should also investigate if the observed association has implications for
transmission of infectious agents, including HIV-1. We did not ﬁnd an
association between fecal microbiome and HBV, HCV, syphillis or rectal
HPV, C. trachomatis or N. gonorrhoeae infections, but did not evaluate
HSV-2 infection. In our study, the observed association between sexual
orientation and microbiota composition did not translate into gross dif-
ferences in terms of systemic inﬂammation or microbial translocation.
Shotgun metagenomic analyses of bacterial species and richness, as
well as the virome and perhaps the mycobiome, in clinical trials
balanced by HIV risk factors might provide novel clues as to the impact
of HIV infection on the gut microbiome.
In conclusion, the fecal microbiota of gay men in Europe is richer
and has a distinct composition. However, HIV-1 infection remains
independently associated with reduced bacterial richness. This offers
new avenues for therapeutic interventions on the gut microbiome
which might improve HIV-associated immune dysfunction.
Author Contributions
R.P., M.N., P.N., A.S., J.B. and B.C. conceived and designed the study.
R.P., I.B., B.M., E.N., J.Co., J.S., A.T., J.N., C.B. and B.C in Barcelona and
P.N., and A.S., in Stockholm, recruited the study participants and per-
formed their clinical evaluations. C.E. performed the dietary assessment.
G.S. and J.C. performed the proctology studies. C.H. coordinated the
study logistics including the fulﬁllment of all ethical and legal require-
ments of the study as member of the Contract Research Organization
overseeing the study, in coordination with R.P. Fecal 16S rDNA was
extracted, ampliﬁed and sequenced by M.P, M.C., M.R. and R.B. under
the supervision of M.N. and R.P. M.R., Y.G, J.R., C.R., F.H. and G.Z.
performed the bioinformatic and statistical analyses of the 16S rDNA
data, with the supervision of M.N., M.L.C., P.B., F.G. and R.P. M.C.
performed the inﬂammation analyses under the supervision of J.Ca.,
J.B and R.P. J.R., did the statistical analyses of the relationship between
the microbiota and inﬂammation and diet, under the supervision
of M.N., M.L.C., F.G. and R.P. F.H and G.Z. performed the multivariate
analysis of factors determining microbiota clusters and ran the conﬁr-
matory analyses with the independent sequence analysis pipeline
LotuS, under supervision of P.B. R.P. wrote the paper, which was
reviewed, edited and approved by all authors.
Conﬂicts of Interest
The authors declare that they have no conﬂicts of interest.
Appendix A. Supplementary Data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.01.032.
References
Arumugam,M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D.R., Fernandes, G.R.,
Tap, J., Bruls, T., Batto, J.-M., Bertalan,M., Borruel, N., Casellas, F., Fernandez, L., Gautier,
L., Hansen, T., Hattori, M., Hayashi, T., Kleerebezem, M., Kurokawa, K., Leclerc, M.,
Levenez, F., Manichanh, C., Nielsen, H.B., Nielsen, T., Pons, N., Poulain, J., Qin, J.,
Sicheritz-Ponten, T., Tims, S., Torrents, D., Ugarte, E., Zoetendal, E.G., Wang, J.,
Guarner, F., Pedersen, O., de Vos, W.M., Brunak, S., Doré, J., Antolín, M., Artiguenave,
F., Blottiere, H.M., Almeida, M., Brechot, C., Cara, C., Chervaux, C., Cultrone, A.,
Delorme, C., Denariaz, G., Dervyn, R., Foerstner, K.U., Friss, C., van de Guchte, M.,
Guedon, E., Haimet, F., Huber, W., van Hylckama-Vlieg, J., Jamet, A., Juste, C., Kaci,
G., Knol, J., Lakhdari, O., Layec, S., Le Roux, K., Maguin, E., Mérieux, A., Melo Minardi,
R., M'rini, C., Muller, J., Oozeer, R., Parkhill, J., Renault, P., Rescigno, M., Sanchez, N.,
Sunagawa, S., Torrejon, A., Turner, K., Vandemeulebrouck, G., Varela, E., Winogradsky,
Y., Zeller, G., Weissenbach, J., Ehrlich, S.D., Bork, P., 2011. Enterotypes of the human
gut microbiome. Nature 473, 174–180. http://dx.doi.org/10.1038/nature09944.Brenchley, J.M., Douek, D.C., 2012. Microbial translocation across the GI tract. Annu.
Rev. Immunol. 30, 149–173. http://dx.doi.org/10.1146/annurev-immunol-
020711-075001.
Brenchley, J.M., Price, D.A., Schacker, T.W., Asher, T.E., Silvestri, G., Rao, S., Kazzaz, Z.,
Bornstein, E., Lambotte, O., Altmann, D., Blazar, B.R., Rodriguez, B., Teixeira-Johnson,
L., Landay, A., Martin, J.N., Hecht, F.M., Picker, L.J., Lederman, M.M., Deeks, S.G.,
Douek, D.C., 2006. Microbial translocation is a cause of systemic immune activation
in chronic HIV infection. Nat. Med. 12, 1365–1371. http://dx.doi.org/10.1038/
nm1511.
Claesson, M.J., Jeffery, I.B., Conde, S., Power, S.E., O'Connor, E.M., Cusack, S., Harris, H.M.B.,
Coakley, M., Lakshminarayanan, B., O'Sullivan, O., Fitzgerald, G.F., Deane, J., O'Connor,
M., Harnedy, N., O'Connor, K., O'Mahony, D., van Sinderen, D., Wallace, M., Brennan,
L., Stanton, C., Marchesi, J.R., Fitzgerald, A.P., Shanahan, F., Hill, C., Ross, R.P., O'Toole,
P.W., 2012. Gut microbiota composition correlates with diet and health in the elderly.
Nature 488, 178–184. http://dx.doi.org/10.1038/nature11319.
Clarke, S.F., Murphy, E.F., O'Sullivan, O., Lucey, A.J., Humphreys, M., Hogan, A., Hayes, P.,
O'Reilly, M., Jeffery, I.B., Wood-Martin, R., Kerins, D.M., Quigley, E., Ross, R.P.,
O'Toole, P.W., Molloy, M.G., Falvey, E., Shanahan, F., Cotter, P.D., 2014. Exercise and
associated dietary extremes impact on gut microbial diversity. Gut 63, 1913–1919.
http://dx.doi.org/10.1136/gutjnl-2013-306541.
Coll, J., Leon, A., Carrillo, A., Fernandez, E., Bravo, I., Saz, J., Meulbroek, M., Pujol, F.,
Gonzalez, V., Casabona, J., Ferrer, L., Blanco, J.L., Piñol, M., Garcia-Cuyas, F., Sirera, G.,
Chamorro, A., Revollo, B., Gatell, J.M., Clotet, B., Brander, C., 2015. Early diagnosis of
HIV infections and detection of asymptomatic STI in a community-based organization
addressed to MSM. 8th IAS Conference on HIV Pathogenesis Treatment and Preven-
tion, 19–22 July 2015 International AIDS Society, Vancouver.
David, L.A., Maurice, C.F., Carmody, R.N., Gootenberg, D.B., Button, J.E., Wolfe, B.E., Ling,
A.V., Devlin, A.S., Varma, Y., Fischbach, M.A., Biddinger, S.B., Dutton, R.J., Turnbaugh,
P.J., 2013. Diet rapidly and reproducibly alters the human gut microbiome. Nature
505, 559–563. http://dx.doi.org/10.1038/nature12820.
Douek, D.C., 2003. Disrupting T-cell homeostasis: how HIV-1 infection causes disease.
AIDS Rev. 5, 172–177.
Fuchs, E.J., Lee, L.A., Torbenson, M.S., Parsons, T.L., Bakshi, R.P., Guidos, A.M., Wahl, R.L.,
Hendrix, C.W., 2007. Hyperosmolar sexual lubricant causes epithelial damage in the
distal colon: potential implication for HIV transmission. J. Infect. Dis. 195, 703–710.
http://dx.doi.org/10.1086/511279.
Goodrich, J.K., Waters, J.L., Poole, A.C., Sutter, J.L., Koren, O., Blekhman, R., Beaumont, M.,
Van Treuren, W., Knight, R., Bell, J.T., Spector, T.D., Clark, A.G., Ley, R.E., 2014.
Human genetics shape the gut microbiome. Cell 159, 789–799. http://dx.doi.org/10.
1016/j.cell.2014.09.053.
Handley, S.A., Thackray, L.B., Zhao, G., Presti, R., Miller, A.D., Droit, L., Abbink, P., Maxﬁeld,
L.F., Kambal, A., Duan, E., Stanley, K., Kramer, J., Macri, S.C., Permar, S.R., Schmitz, J.E.,
Mansﬁeld, K., Brenchley, J.M., Veazey, R.S., Stappenbeck, T.S., Wang, D., Barouch, D.H.,
Virgin, H.W., 2012. Pathogenic simian immunodeﬁciency virus infection is associated
with expansion of the enteric virome. Cell 151, 253–266. http://dx.doi.org/10.1016/j.
cell.2012.09.024.
Hildebrand, F., Tadeo, R., Voigt, A.Y., Bork, P., Raes, J., 2014. LotuS: an efﬁcient and user-
friendly OTU processing pipeline. Microbiome 2, 1–7. http://dx.doi.org/10.1186/
2049-2618-2-30.
Koeth, R.A., Wang, Z., Levison, B.S., Buffa, J.A., Org, E., Sheehy, B.T., Britt, E.B., Fu, X., Wu, Y.,
Li, L., Smith, J.S., DiDonato, J.A., Chen, J., Li, H.,Wu, G.D., Lewis, J.D., Warrier, M., Brown,
J.M., Krauss, R.M., Tang, W.H.W., Bushman, F.D., Lusis, A.J., Hazen, S.L., 2013. Intestinal
microbiota metabolism of L-carnitine, a nutrient in red meat, promotes
atherosclerosis. Nat. Med. 19, 533–534. http://dx.doi.org/10.1038/nm.3178.
Koren, O., Knights, D., Gonzalez, A., Waldron, L., Segata, N., Knight, R., Huttenhower, C.,
Ley, R.E., 2013. A guide to enterotypes across the human body: meta-analysis of
microbial community structures in human microbiome datasets. PLoS Comput. Biol.
9, e1002863. http://dx.doi.org/10.1371/journal.pcbi.1002863.
Koropatkin, N.M., Cameron, E.A., Martens, E.C., 2012. How glycan metabolism shapes the
human gut microbiota. Nat. Rev. Microbiol. 10, 323–335. http://dx.doi.org/10.1038/
nrmicro2746.
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M.,
Arumugam, M., Batto, J.-M., Kennedy, S., Leonard, P., Li, J., Burgdorf, K., Grarup,
N., Jørgensen, T., Brandslund, I., Nielsen, H.B., Juncker, A.S., Bertalan, M.,
Levenez, F., Pons, N., Rasmussen, S., Sunagawa, S., Tap, J., Tims, S., Zoetendal,
E.G., Brunak, S., Clément, K., Doré, J., Kleerebezem, M., Kristiansen, K., Renault,
P., Sicheritz-Ponten, T., de Vos, W.M., Zucker, J.-D., Raes, J., Hansen, T., Bork, P.,
Wang, J., Ehrlich, S.D., Pedersen, O., Guedon, E., Delorme, C., Layec, S., Khaci, G.,
van de Guchte, M., Vandemeulebrouck, G., Jamet, A., Dervyn, R., Sanchez, N.,
Maguin, E., Haimet, F., Winogradski, Y., Cultrone, A., Leclerc, M., Juste, C.,
Blottière, H., Pelletier, E., LePaslier, D., Artiguenave, F., Bruls, T., Weissenbach, J.,
Turner, K., Parkhill, J., Antolin, M., Manichanh, C., Casellas, F., Boruel, N., Varela,
E., Torrejon, A., Guarner, F., Denariaz, G., Derrien, M., van Hylckama Vlieg, J.E.T.,
Veiga, P., Oozeer, R., Knol, J., Rescigno, M., Brechot, C., M'Rini, C., Mérieux, A.,
Yamada, T., 2013. Richness of human gut microbiome correlates with metabolic
markers. Nature 500, 541–546. http://dx.doi.org/10.1038/nature12506.
Lozupone, C.A., Li, M., Campbell, T.B., Flores, S.C., Linderman, D., Gebert, M., Knight, R.,
Fontenot, A.P., Palmer, B.E., 2013. Alterations in the gut microbiota associated with
HIV-1 infection. Cell Host Microbe 14, 329–339. http://dx.doi.org/10.1016/j.chom.
2013.08.006.Alterations.
Manichanh, C., Borruel, N., Casellas, F., Guarner, F., 2012. The gut microbiota in IBD.
Nat. Rev. Gastroenterol. Hepatol. 9, 599–608. http://dx.doi.org/10.1038/
nrgastro.2012.152.
McGowan, I., 2012. Rectal microbicide development. curr. opin. HIV AIDS 7, 526–533.
Meulbroek, M., Ditzel, E., Saz, J., Taboada, H., Pérez, F., Pérez, A., Carrillo, A., Font, G.,
Marazzi, G., Uya, J., Cabrero, J., Ingrami, M., Marín, R., Coll, J., Pujol, F., 2013. BCN
146 M. Noguera-Julian et al. / EBioMedicine 5 (2016) 135–146Checkpoint, a community-based centre formenwho have sexwithmen in Barcelona,
Catalonia, Spain, shows high efﬁciency in HIV detection and linkage to care. HIVMed.
14, 25–28. http://dx.doi.org/10.1111/hiv.12054.
Modi, S., Collins, J., Relman, D., 2014. Antibiotics and the gut microbiota. J. Clin. Invest. 124,
4212–4218. http://dx.doi.org/10.1172/JCI72333.The.
Mutlu, E.A., Keshavarzian, A., Losurdo, J., Swanson, G., Siewe, B., Forsyth, C., French, A.,
Demarais, P., Sun, Y., Koenig, L., Cox, S., Engen, P., Chakradeo, P., Abbasi, R., Gorenz,
A., Burns, C., Landay, A., 2014. A compositional look at the human gastrointestinal
microbiome and immune activation parameters in HIV infected subjects. PLoS
Pathog. 10 http://dx.doi.org/10.1371/journal.ppat.1003829.
Nowak, P., Troseid, M., Avershina, E., Barqasho, B., Neogi, U., Holm, K., Hov, J.R., Noyan, K.,
Vesterbacka, J., Svärd, J., Rudi, K., Sönnerborg, A., 2015. Gut microbiota diversity
predicts immune status in HIV-1 infection. AIDS 29, 2409–2418.
Paiardini, Müller-Trutwin, M., 2013. HIV-associated chronic immune activation. Immunol.
Rev. 254, 78–101. http://dx.doi.org/10.1111/imr.12079.
Sandler, N.G., Douek, D.C., 2012. Microbial translocation in HIV infection: causes,
consequences and treatment opportunities. Nat. Rev. Microbiol. 10, 655–666.
http://dx.doi.org/10.1038/nrmicro2848.
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W.S., Huttenhower, C.,
2011. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60.
http://dx.doi.org/10.1186/gb-2011-12-6-r60.
Sommer, F., Bäckhed, F., 2013. The gut microbiota — masters of host development and
physiology. Nat. Rev. Microbiol. 11, 227–238. http://dx.doi.org/10.1038/nrmicro2974.Tang, W.H.W., Wang, Z., Levison, B.S., Koeth, R.a., Britt, E.B., Fu, X., Wu, Y., Hazen,
S.L., 2013. Intestinal microbial metabolism of phosphatidylcholine and cardio-
vascular risk. N. Engl. J. Med. 368, 1575–1584. http://dx.doi.org/10.1056/
NEJMoa1109400.
Vázquez-Castellano, J.F., Serrano-Villar, S., Latorre, A., Artacho, A., Ferrus, M.L., Madrid, N.,
Vallejo, A., Sainz, T., Martinez-Botas, J., Ferrando-Martinez, S., Vera, M., Dronda, F.,
Leal, M., del Romero, J., Moreno, S., Estrada, V., Gosalbes, M.J., Moya, A., 2015.
Altered metabolism of gut microbiota contributes to chronic immune activation
in HIV-infected individuals. Mucosal. Immunol. 8, 760–762. http://dx.doi.org/10.
1038/mi.2014.107.
Wu, G.D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y., Keilbaugh, S.A., Bewtra, M., Knights,
D., Walters, W.A., Knight, R., Sinha, R., Gilroy, E., Gupta, K., Baldassano, R., Nessel, L., Li,
H., 2011. Linking long-term dietary patterns with gut microbial enterotypes. Science
334, 105–108.
Yu, G., Fadrosh, D., Ma, B., Ravel, J., Goedert, J.J., 2013. Anal microbiota proﬁles in HIV-
positive and HIV-negative MSM. AIDS 28, 753–760. http://dx.doi.org/10.1097/QAD.
0000000000000154.
Zeller, G., Tap, J., Voigt, A.Y., Sunagawa, S., Kultima, J.R., Paul, I., Amiot, A., Böhm, J.,
Brunetti, F., Habermann, N., Hercog, R., Koch, M., Luciani, A., Mende, D.R., Schneider,
M.A., Schrotz-king, P., Tournigand, C., Nhieu, J.T. Van, Yamada, T., Zimmermann, J.,
2014. Potential of fecal microbiota for early-stage detection of colorectal cancer.
Mol. Syst. Biol. 10, 1–18.
